$AURX
Nuo Therapeutics Inc Stock $aurx

$aurx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000143774922009050 Filed on April 15, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change
Gross Profit	$0.00	$0.00	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$71.65K	$6.751K	$6.546K
YoY Change	-77.61%	7.95%	13.0%
% of Gross Profit
Research & Development	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$71.65K	$6.751K	$6.546K
YoY Change	-77.61%	7.95%	13.0%
Operating Profit	-$71.65K	-$6.751K	-$6.546K
YoY Change	-77.61%	7.95%	13.0%
Interest Expense	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$0.00
YoY Change		-100.0%
Pretax Income	-$71.65K	-$6.751K	-$6.546K
YoY Change	-68.85%	-56.39%	-71.45%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$71.65K	-$6.751K	-$6.546K
YoY Change	-100.95%	-56.39%	-71.45%
Net Earnings / Revenue
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share	-$2.356K	-$223.10	-$216.50
COMMON SHARES
Basic Shares Outstanding		30.26M	30.26M
Diluted Shares Outstanding		30.26M	30.26M

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.415M	$148.4K	$151.6K
YoY Change	784.11%
Cash & Equivalents	$1.415M	$148.4K	$151.6K
Short-Term Investments
Other Short-Term Assets	$51.35K	$1.500K	$1.500K
YoY Change
Inventory	$0.00
Prepaid Expenses
Receivables	$0.00
Other Receivables
Total Short-Term Assets	$1.466M	$149.9K	$153.1K
YoY Change	808.07%		1177476.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$0.00	$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$1.466M	$149.9K	$153.1K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$1.466M	$149.9K	$153.1K
YoY Change	808.07%		1177476.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$526.6K	$525.9K	$522.3K
YoY Change	1.57%	-1.88%	-1.41%
Accrued Expenses	$146.5K	$146.5K	$146.5K
YoY Change	0.0%	-10.21%	-10.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$673.1K	$672.5K	$668.9K
YoY Change	1.22%	-35.0%	-34.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$673.1K	$672.5K	$668.9K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$673.1K	$672.5K	$668.9K
YoY Change	1.22%	-35.0%	-34.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$23.59M	-$23.52M	-$23.51M
YoY Change	0.39%	1.09%	1.13%
Common Stock	$3.713K	$3.026K	$3.026K
YoY Change	22.7%	24.78%	24.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$792.8K	-$522.5K	-$515.8K
YoY Change
Total Liabilities & Shareholders Equity	$1.466M	$149.9K	$153.1K
YoY Change	808.07%		1177476.92%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021 Q2
OPERATING ACTIVITIES
Net Income	-$71.65K	-$6.751K	-$6.546K
YoY Change	-100.95%	-56.39%	-71.45%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$107.0K	-$3.150K	-$5.680K
YoY Change	256.53%		-43.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.373M	0.000	0.000
YoY Change	586.55%
NET CHANGE
Cash From Operating Activities	-107.0K	-3.150K	-5.680K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	1.373M	0.000	0.000
Net Change In Cash	1.266M	-3.150K	-5.680K
YoY Change	644.78%		-43.2%
FREE CASH FLOW
Cash From Operating Activities	-$107.0K	-$3.150K	-$5.680K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Auditor Location AuditorLocation	Houston, Texas
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29038
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29038
CY2019Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	29038000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37124205
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37124205
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30258744
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30258744
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23722400
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23722400
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	USD
CY2019Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	146000	USD
CY2020	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2018	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0	USD
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30258744
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30258744
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30258744
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30258744
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30258744
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30258744
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29038
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29038
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29038
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29038
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29038
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29038
CY2020Q3	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	29038000	USD
CY2020Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	29038000	USD
CY2020Q1	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	29038000	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24247400
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24247400
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24247400
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24247400
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24247400
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24247400
CY2019Q4	us-gaap	Assets Assets	276548	USD
CY2020Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	USD
CY2020Q4	us-gaap	Assets Assets	161432	USD
CY2020Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	USD
CY2021Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	USD
CY2021Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	USD
CY2021Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	USD
CY2020Q1	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0	USD
CY2020Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0	USD
CY2020Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0	USD
CY2021Q1	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2018	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2021Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0	USD
CY2021Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1414569	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	161432	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20253	USD
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	USD
CY2020Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	USD
CY2019Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	220000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	51349	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	0	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	36295	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1465918	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	161432	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	276548	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2021Q4	us-gaap	Assets Assets	1465918	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	526557	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	518429	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	538669	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	146522	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	146522	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	173189	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	61053	USD
CY2021Q4	us-gaap	Senior Notes Current SeniorNotesCurrent	0	USD
CY2020Q4	us-gaap	Senior Notes Current SeniorNotesCurrent	0	USD
CY2019Q4	us-gaap	Senior Notes Current SeniorNotesCurrent	288971	USD
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2019Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	410000	USD
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	13784	USD
CY2021	us-gaap	Gross Profit GrossProfit	0	USD
CY2020	us-gaap	Gross Profit GrossProfit	0	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	114614	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	673079	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	664951	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1485666	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2021Q4	us-gaap	Liabilities Liabilities	673079	USD
CY2020Q4	us-gaap	Liabilities Liabilities	664951	USD
CY2019Q4	us-gaap	Liabilities Liabilities	1485666	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	3	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3713	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3026	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	2372	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24382195	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22995854	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22200036	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23593069	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23502399	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23411529	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	792839	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-503519	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-1209118	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1465918	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	161432	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	276548	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	146177	USD
CY2019	us-gaap	Gross Profit GrossProfit	31563	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	30457	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	181185	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	90670	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	378059	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	789119	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	90670	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	378059	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	1000761	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-90670	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-378059	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-969198	USD
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-48390	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-221459	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	335579	USD
CY2020	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	158381	USD
CY2019	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	-0	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-886262	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7708824	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1194894	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30296376
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25692248
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23722400
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30296376
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4237	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-90670	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-90870	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1194894	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-90670	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-90870	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-1194894	USD
CY2021	aurx	Gain On Exchange Of Preferred Stock GainOnExchangeOfPreferredStock	0	USD
CY2020	aurx	Gain On Exchange Of Preferred Stock GainOnExchangeOfPreferredStock	7958075	USD
CY2019	aurx	Gain On Exchange Of Preferred Stock GainOnExchangeOfPreferredStock	0	USD
CY2021	aurx	Warrant Modification Amount WarrantModificationAmount	795592	USD
CY2020	aurx	Warrant Modification Amount WarrantModificationAmount	-0	USD
CY2019	aurx	Warrant Modification Amount WarrantModificationAmount	-0	USD
CY2021	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	-0	USD
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27312176
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23722400
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-81987	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	17763	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-1194894	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-1209118	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	333628	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	21000	USD
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10501	USD
CY2020	aurx	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	0	USD
CY2020	aurx	Stock Issued During Period Value Settlement Of Preferred Stock And Options StockIssuedDuringPeriodValueSettlementOfPreferredStockAndOptions	0	USD
CY2020	aurx	Stock And Warrants Issued During Period Value Replacement Of Existing Warrants StockAndWarrantsIssuedDuringPeriodValueReplacementOfExistingWarrants	431340	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-90870	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-503519	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13936	USD
CY2021	aurx	Stock Issued During Period Value Inducement Of Warrants StockIssuedDuringPeriodValueInducementOfWarrants	1373092	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-90670	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	792839	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-90670	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-90870	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-1194894	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	89859	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	13936	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	102724	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-0	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-0	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-15620	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	335579	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	USD
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-0	USD
CY2020	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-0	USD
CY2019	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	220000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-0	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-0	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-22170	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-25348	USD
CY2021	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	51349	USD
CY2020	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-36295	USD
CY2019	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-145948	USD
CY2021	aurx	Increase Decrease In Deferred Charges And Other Assets IncreaseDecreaseInDeferredChargesAndOtherAssets	-0	USD
CY2020	aurx	Increase Decrease In Deferred Charges And Other Assets IncreaseDecreaseInDeferredChargesAndOtherAssets	-0	USD
CY2019	aurx	Increase Decrease In Deferred Charges And Other Assets IncreaseDecreaseInDeferredChargesAndOtherAssets	-3330	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	8128	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-29520	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	101344	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	333628	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	50000	USD
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	10501	USD
CY2019	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16029	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-26667	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-112010	USD
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	32362	USD
CY2019	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	48887	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-119955	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53821	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-921674	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	305000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	195000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1373092	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1373092	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	195000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	305000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1253137	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	141179	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-616674	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	161432	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20253	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	636927	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1414569	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	161432	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20253	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	69000	USD
CY2021	aurx	Resetting Of Warrant Exercise Price ResettingOfWarrantExercisePrice	0	USD
CY2020	aurx	Resetting Of Warrant Exercise Price ResettingOfWarrantExercisePrice	158381	USD
CY2019	aurx	Resetting Of Warrant Exercise Price ResettingOfWarrantExercisePrice	0	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	10501	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Description of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Description of Business</span></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Nuo Therapeutics, Inc. (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a Delaware corporation organized in <em style="font: inherit;">1998</em> under the name Informatix Holdings, Inc. In <em style="font: inherit;">1999,</em> Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc. In <em style="font: inherit;">2000,</em> Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc. (“Cytomedix”). In <em style="font: inherit;">2001,</em> Cytomedix, filed for bankruptcy under Chapter <em style="font: inherit;">11</em> of the United States Bankruptcy Code, after which Cytomedix was authorized to continue to conduct its business as a debtor and debtor-in-possession. Cytomedix emerged from bankruptcy in <em style="font: inherit;">2002</em> under a Plan of Reorganization. In <em style="font: inherit;"> September 2007, </em>Cytomedix received <em style="font: inherit;">510</em>(k) clearance for the Aurix System (“Aurix”), formerly known as the AutoloGel™ System, from the U. S. Food and Drug Administration (“FDA”). In <em style="font: inherit;"> April 2010, </em>Cytomedix acquired the Angel Whole Blood Separation System (“Angel”) and the Angel Business, from Sorin Group USA, Inc. In <em style="font: inherit;"> February 2012, </em>Cytomedix, acquired Aldagen, Inc. (“Aldagen”), a privately held developmental cell-therapy company located in Durham, NC. In <em style="font: inherit;">2014,</em> Cytomedix changed its name to Nuo Therapeutics, Inc. In <em style="font: inherit;">2016,</em> Nuo filed for and emerged from bankruptcy under Chapter <em style="font: inherit;">11</em> as described previously under “<i>Item <em style="font: inherit;">1.</em> Business </i>– <i><em style="font: inherit;">2016</em></i> <i>Bankruptcy and Emergence from Bankruptcy</i>.” Effective <em style="font: inherit;"> May 1, 2019, </em>we furloughed our remaining employees and ceased standard operational activities as we awaited developments concerning our reconsideration request with the Centers for Medicare & Medicaid Services (“CMS”) regarding Medicare coverage for Aurix. Based on a favorable National Coverage Determination issued in <em style="font: inherit;"> April 2021, </em>we initiated restart activities for the business beginning in <em style="font: inherit;"> October 2021 </em>with an expectation that the Aurix product will be available for commercial sale by <em style="font: inherit;"> May 2022. </em>Aldagen is a non-operational, wholly owned subsidiary of Nuo.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Impact of COVID-<em style="font: inherit;">19</em> Pandemic on Financial Statements </span></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> March 11, 2020, </em>the World Health Organization declared the outbreak of COVID-<em style="font: inherit;">19</em> as a “pandemic,” or a worldwide spread of anew disease. Many countries imposed and continue to enforce quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In response to COVID- <em style="font: inherit;">19,</em> the Company has <em style="font: inherit;">not</em> experienced a significant disruption or delay in the development, manufacturing or sale of its products and has <em style="font: inherit;">not</em> otherwise experienced any significant negative impact on its financial condition, results of operations or cash flows. However, the extent to which COVID-<em style="font: inherit;">19</em> <em style="font: inherit;"> may </em>impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the pandemic. The consolidated financial statements do <em style="font: inherit;">not</em> include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has <em style="font: inherit;">not</em> experienced any significant negative impact on the <em style="font: inherit;"> December 31, 2021 </em>audited consolidated financial statements related to COVID-<em style="font: inherit;">19.</em></p>
CY2020Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	487500
CY2020Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	195000	USD
CY2020Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	487500
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.40
CY2020Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	195000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1873092	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23600000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1400000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Use of Estimates</span></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but <em style="font: inherit;">not</em> limited to stock-based compensation, the fair value of common stock and equity-linked and derivative financial instruments, recoverability and depreciable lives of long-lived assets, deferred taxes and associated valuation allowance, the valuation and classification of debt instruments, and allowances for inventory obsolescence and doubtful accounts. Actual results could differ from those estimates.</p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Credit Concentration</span></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="-sec-ix-hidden:c83066931">One</span> customer generated 26% of our revenue in <em style="font: inherit;">2019.</em> All our revenue in <em style="font: inherit;">2019</em> was generated within the U.S. We had no trade receivables as of <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019</em> given our <em style="font: inherit;"> April 2019 </em>decision to cease operational activities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Historically, we used single suppliers for several components of the Aurix™ product line. We outsource the manufacturing of various product components to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is <em style="font: inherit;">no</em> assurance that <em style="font: inherit;">one</em> or more of them will <em style="font: inherit;">not</em> experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of Aurix™ are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an established vendor relationship.</p>
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	USD
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1400000	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-15620	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0026	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0033	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2019	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-90670	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-90870	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-1194894	USD
CY2021	aurx	Gain On Exchange Of Preferred Stock GainOnExchangeOfPreferredStock	0	USD
CY2020	aurx	Gain On Exchange Of Preferred Stock GainOnExchangeOfPreferredStock	7958075	USD
CY2019	aurx	Gain On Exchange Of Preferred Stock GainOnExchangeOfPreferredStock	0	USD
CY2021	aurx	Warrant Modification Amount WarrantModificationAmount	795592	USD
CY2020	aurx	Warrant Modification Amount WarrantModificationAmount	-0	USD
CY2019	aurx	Warrant Modification Amount WarrantModificationAmount	-0	USD
CY2021	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	-0	USD
CY2020	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	158381	USD
CY2019	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	-0	USD
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	795592	USD
CY2020	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-7799694	USD
CY2019	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-0	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-886262	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7708824	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1194894	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30296376
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25692248
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23722400
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-886262	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7708824	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1194894	USD
CY2021	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2020	us-gaap	Dilutive Securities DilutiveSecurities	-241138	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1588334
CY2019	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-886262	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	7467686	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1194894	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30296376
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27312176
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23722400
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14633795
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31858610
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	103333	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	103333	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	120000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	33189	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	33189	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	33189	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	20000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	146522	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	146522	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	173189	USD
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	48390	USD
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	221459	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	40990	USD
CY2019Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	61053	USD
CY2020Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	233333
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13278794
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7104166
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6646666
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.56
CY2018	aurx	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm	P2Y6M3D
CY2019	aurx	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	457500
CY2019	aurx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	0.40
CY2019	aurx	Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Term ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualTerm	P5Y
CY2019	aurx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	0
CY2019	aurx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	0
CY2019	aurx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	0
CY2019	aurx	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	0
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7104166
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.55
CY2019	aurx	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm	P1Y8M23D
CY2021Q4	aurx	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	233333
CY2021Q4	aurx	Class Of Warrant Or Right Exercisable Exercise Price ClassOfWarrantOrRightExercisableExercisePrice	0.15
CY2021	aurx	Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm	P1Y8M15D
CY2021Q4	aurx	Authorized Shares Common And Preferred AuthorizedSharesCommonAndPreferred	101000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2020	aurx	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	6865461
CY2020	aurx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	0.40
CY2020	aurx	Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Term ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualTerm	P5Y
CY2020	aurx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	233333
CY2020	aurx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	-0.15
CY2020	aurx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	-457500
CY2020	aurx	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	-0.40
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13278794
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.49
CY2020	aurx	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm	P2Y8M1D
CY2021	aurx	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	0
CY2021	aurx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	0
CY2021	aurx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-6865461
CY2021	aurx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	-0.40
CY2021	aurx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	-6180000
CY2021	aurx	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	-0.59
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	233333
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.15
CY2021	aurx	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm	P1Y8M15D
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	7958075	USD
CY2020	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	175000
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10501	USD
CY2020	aurx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	233333
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	21048	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	24203	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	311164	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	16114	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	19083	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	249403	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4934	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	5120	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	61761	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	21048	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	24203	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	311164	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39601242	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39493700	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39428019	USD
CY2021Q4	aurx	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	356956	USD
CY2020Q4	aurx	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	443451	USD
CY2019Q4	aurx	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	529946	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	86506	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	82912	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	37895	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40044704	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40020063	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	39995860	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40044704	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40020063	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	39995860	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.232	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.266	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.260	pure
CY2021	aurx	Effective Income Tax Rate Reconciliation Nondeductible Expense And Other Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAndOtherPercent	0.026	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.048	pure
CY2020	aurx	Effective Income Tax Rate Reconciliation Nondeductible Expense And Other Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAndOtherPercent	-0.009	pure
CY2019	aurx	Effective Income Tax Rate Reconciliation Nondeductible Expense And Other Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAndOtherPercent	-0.003	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	33600000	USD
CY2018Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	13784	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.048	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.048	pure
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	39500	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148430	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	151585	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	157264	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1500	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1500	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	0	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	149930	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	153085	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	157264	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2020Q1	us-gaap	Interest Payable Current InterestPayableCurrent	12046	USD
CY2021Q3	us-gaap	Assets Assets	149930	USD
CY2021Q2	us-gaap	Assets Assets	153085	USD
CY2021Q1	us-gaap	Assets Assets	157264	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	525945	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	522349	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	519982	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	146522	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	146522	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	146522	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	672467	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	668871	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	666504	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2021Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2021Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2021Q3	us-gaap	Liabilities Liabilities	672467	USD
CY2021Q2	us-gaap	Liabilities Liabilities	668871	USD
CY2021Q1	us-gaap	Liabilities Liabilities	666504	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	3026	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	3026	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	3026	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22995854	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22995854	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22995854	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23521417	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23514666	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23508120	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-522537	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-515786	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-509240	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	149930	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153085	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	157264	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11209	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	0	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	0	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	897	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	0	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	13	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	12106	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2020Q3	us-gaap	Assets Assets	0	USD
CY2020Q2	us-gaap	Assets Assets	13	USD
CY2020Q1	us-gaap	Assets Assets	12106	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	536044	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	529803	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	536103	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	163189	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	163189	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	163189	USD
CY2020Q3	us-gaap	Interest Payable Current InterestPayableCurrent	30396	USD
CY2020Q2	us-gaap	Interest Payable Current InterestPayableCurrent	21171	USD
CY2020Q3	us-gaap	Senior Notes Current SeniorNotesCurrent	305000	USD
CY2020Q2	us-gaap	Senior Notes Current SeniorNotesCurrent	305000	USD
CY2020Q1	us-gaap	Senior Notes Current SeniorNotesCurrent	296986	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1034629	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1019163	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1008324	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2020Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2020Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2020Q3	us-gaap	Liabilities Liabilities	1034629	USD
CY2020Q2	us-gaap	Liabilities Liabilities	1019163	USD
CY2020Q1	us-gaap	Liabilities Liabilities	1008324	USD
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	3	USD
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	3	USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	3	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	2425	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	2425	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	2425	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22231484	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22231484	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22231484	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23268541	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23253062	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23230130	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-1034629	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-1019150	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-996218	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity		USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12106	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
	us-gaap	Gross Profit GrossProfit	0	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	0	USD
	us-gaap	Gross Profit GrossProfit	0	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	0	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	0	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19018	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6751	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12267	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6546	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5721	USD
	us-gaap	Operating Expenses OperatingExpenses	19018	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	6751	USD
	us-gaap	Operating Expenses OperatingExpenses	12267	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	6546	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6751	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12267	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6546	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5721	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19018	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	5721	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19018	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6751	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12267	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6546	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5721	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19018	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-6751	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12267	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6546	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5721	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30258744
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30258744
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30258744
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30258744
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30258744
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30258744
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30258744
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30258744
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30258744
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30258744
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-22932	USD
	us-gaap	Gross Profit GrossProfit	0	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	0	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	0	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42378	USD
	us-gaap	Operating Expenses OperatingExpenses	54425	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13002	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9847	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4168	USD
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	6254	USD
	us-gaap	Operating Expenses OperatingExpenses	48171	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	5793	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	42378	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54425	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6254	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-48171	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
	us-gaap	Gross Profit GrossProfit	0	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	54425	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6254	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48171	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5793	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5793	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-42378	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-48390	USD
CY2020Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-9225	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-39165	USD
CY2020Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-17139	USD
CY2020Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-22026	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	245803	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	245803	USD
CY2020Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	245803	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	142988	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15479	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	158467	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22932	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	181399	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	142988	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-15479	USD
	us-gaap	Net Income Loss NetIncomeLoss	158467	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-1034629	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	181399	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24152874
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24247400
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24105092
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24247400
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23962785
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26310807
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24247400
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27353849
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24247400
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30460299
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-1209118	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	21000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10501	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	181399	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-996218	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-22932	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-1019150	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-15479	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-503519	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5721	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-509240	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6546	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-515786	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-6751	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-522537	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19018	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12267	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5721	USD
	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	1500	USD
	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	1500	USD
CY2021Q1	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7516	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3920	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1553	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13002	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9847	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4168	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2021Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	142988	USD
	us-gaap	Net Income Loss NetIncomeLoss	158467	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	181399	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	10501	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	10501	USD
CY2020Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	10501	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	16029	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	16029	USD
	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-36295	USD
	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-36295	USD
CY2020Q1	aurx	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-35398	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	161432	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	161432	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	161432	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148430	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	151585	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	157264	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	8015	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	245803	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	245803	USD
CY2020Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	245803	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2625	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-8866	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2566	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	32362	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	23137	USD
CY2020Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	14012	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20253	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20240	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9044	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20253	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20240	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9044	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20253	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20253	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20253	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11209	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Stock Issued1 StockIssued1	10501	USD
	us-gaap	Stock Issued1 StockIssued1	10501	USD
CY2020Q1	us-gaap	Stock Issued1 StockIssued1	10501	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Description of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Description of Business</span></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Nuo Therapeutics, Inc. (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a Delaware corporation organized in <em style="font: inherit;">1998</em> under the name Informatix Holdings, Inc. In <em style="font: inherit;">1999,</em> Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc. In <em style="font: inherit;">2000,</em> Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc. (“Cytomedix”). In <em style="font: inherit;">2001,</em> Cytomedix, filed for bankruptcy under Chapter <em style="font: inherit;">11</em> of the United States Bankruptcy Code, after which Cytomedix was authorized to continue to conduct its business as a debtor and debtor-in-possession. Cytomedix emerged from bankruptcy in <em style="font: inherit;">2002</em> under a Plan of Reorganization. In <em style="font: inherit;"> September 2007, </em>Cytomedix received <em style="font: inherit;">510</em>(k) clearance for the Aurix System (“Aurix”), formerly known as the AutoloGel™ System, from the U. S. Food and Drug Administration (“FDA”). In <em style="font: inherit;"> April 2010, </em>Cytomedix acquired the Angel Whole Blood Separation System (“Angel”) and the Angel Business, from Sorin Group USA, Inc. In <em style="font: inherit;"> February 2012, </em>Cytomedix, acquired Aldagen, Inc. (“Aldagen”), a privately held developmental cell-therapy company located in Durham, NC. In <em style="font: inherit;">2014,</em> Cytomedix changed its name to Nuo Therapeutics, Inc. In <em style="font: inherit;">2016,</em> Nuo filed for and emerged from bankruptcy under Chapter <em style="font: inherit;">11</em> as described previously under “<i>Item <em style="font: inherit;">1.</em> Business </i>– <i><em style="font: inherit;">2016</em></i> <i>Bankruptcy and Emergence from Bankruptcy</i>.” Effective <em style="font: inherit;"> May 1, 2019, </em>we furloughed our remaining employees and ceased standard operational activities as we awaited developments concerning our reconsideration request with the Centers for Medicare & Medicaid Services (“CMS”) regarding Medicare coverage for Aurix. Based on a favorable National Coverage Determination issued in <em style="font: inherit;"> April 2021, </em>we initiated restart activities for the business beginning in <em style="font: inherit;"> October 2021 </em>with an expectation that the Aurix product will be available for commercial sale by <em style="font: inherit;"> May 2022. </em>Aldagen is a non-operational, wholly owned subsidiary of Nuo.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Use of Estimates</span></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but <em style="font: inherit;">not</em> limited to, stock-based compensation, allowance for inventory obsolescence, allowance for doubtful accounts, contingent liabilities, fair value and depreciable lives of long-lived assets (including property and equipment, intangible assets and goodwill), deferred taxes and associated valuation allowance and the classification of our long-term debt. Actual results could differ from those estimates.</p>
	us-gaap	Net Income Loss NetIncomeLoss	142988	USD
	us-gaap	Net Income Loss NetIncomeLoss	158467	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	181399	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24152874
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24105092
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23962785
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	142988	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	158467	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	181399	USD
	us-gaap	Dilutive Securities DilutiveSecurities	-241138	USD
	us-gaap	Dilutive Securities DilutiveSecurities	-241138	USD
CY2020Q1	us-gaap	Dilutive Securities DilutiveSecurities	-241138	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-98150	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-82671	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-59739	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26310807
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27353849
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30460299
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8453795
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8453795
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14633795
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8459167
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8459167
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8459167
CY2020Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	175000
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7088794
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7088794
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13268794
CY2020Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7104166
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7104166
CY2020Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7104166
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
CY2018Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	13784	USD
CY2020Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	USD

Files In Submission

Name	View Source	Status
0001437749-22-009050-index-headers.html	Edgar Link	pending
0001437749-22-009050-index.html	Edgar Link	pending
0001437749-22-009050.txt	Edgar Link	pending
0001437749-22-009050-xbrl.zip	Edgar Link	pending
aurx-20211231.xsd	Edgar Link	pending
aurx-20211231_cal.xml	Edgar Link	unprocessable
aurx-20211231_def.xml	Edgar Link	unprocessable
aurx-20211231_lab.xml	Edgar Link	unprocessable
aurx-20211231_pre.xml	Edgar Link	unprocessable
aurx20211231b_10k.htm	Edgar Link	pending
aurx20211231b_10kimg001.jpg	Edgar Link	pending
aurx20211231b_10k_htm.xml	Edgar Link	completed
ex_355197.htm	Edgar Link	pending
ex_355198.htm	Edgar Link	pending
ex_355199.htm	Edgar Link	pending
ex_355200.htm	Edgar Link	pending
ex_356261.htm	Edgar Link	pending
ex_358586.htm	Edgar Link	pending
ex_359202.htm	Edgar Link	pending
ex_359203.htm	Edgar Link	pending
ex_359204.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AURX
Nuo Therapeutics Inc Stock $aurx

2021 Q4 Form 10-K Financial Statement

#000143774922009050 Filed on April 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AURX Nuo Therapeutics Inc Stock $aurx

2021 Q4 Form 10-K Financial Statement

#000143774922009050 Filed on April 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AURX
Nuo Therapeutics Inc Stock $aurx